Sensus Healthcare to Exhibit at the 2017 American Association of Physicists in Medicine Annual Meeting
BOCA RATON, Fla. – July 19, 2017 – Sensus Healthcare, Inc. (NASDAQ: SRTS), a medical device company specializing in the treatment of non-melanoma skin cancers (NMSC) and other skin conditions, such as keloids with Superficial Radiation Therapy (SRT), announced that the Company will be exhibiting at the 2017 American Association of Physicists in Medicine (AAPM) Annual Meeting in Denver, Colo., on July 30 through August 3.
At AAPM, Sensus will share information about its premier product for radiation oncologists: the SRT-100 Vision, which utilizes the Company’s proprietary, low-energy X-ray radiation technology to effectively, painlessly and safely treat oncological and non-oncological skin conditions. The device delivers precise, calibrated SRT doses while offering high-frequency ultrasound for imaging that allows physicians to create the most effective treatment plans possible for patients, as well as better examine how the lesion is shrinking over time. It also records each session for the patient’s records via the LesionCamTM.
“As the first doctor in Colorado to use SRT, and having used the technology regularly for the past 18+ months, I can tell you that this alternative treatment to surgery is not only highly effective and non-invasive but also perfect for patients who are surgically fatigued from multiple surgeries over time,” said Dr. Kevin Schewe, radiation oncologist at Alliance Cancer Care Colorado at Red Rocks. “SRT provides patients with a treatment option that rivals the effectiveness and cure rate of surgery but requires no scalpels, no needles and no surgical scars. Sensus Healthcare’s innovative technology has been a tremendous addition to the patient care that we provide.”
“SRT is a game-changer when it comes to treating non-melanoma skin cancer and keloids, and we look forward to connecting with some of the country’s leading radiation oncologists who are in attendance at AAPM this year to share our knowledge and spread the word,” added Joe Sardano, CEO, Sensus Healthcare. “Both patients and doctors benefit greatly from SRT in that the treatment is painless and doesn’t require anesthesia, cutting or stitching and ultimately improves physician productivity by allowing doctors to treat more patients. It’s a win-win for everyone involved.”
For more information on Sensus Healthcare and the SRT-100 Vision, please visit Booth No. 7045 at AAPM in the Colorado Convention Center.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiotherapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit https://www.sensushealthcare.com.
Caitlin Kasunich / Nick Opich
KCSA Strategic Communications
212-896-1241 / 212-896-1206
The Benefits of SRT
Along with eliminating the risks for post-surgical infections and complications, the SRT-100™ provides patients and physicians with a safe and effective treatment option that offers many benefits, including:
- 95%+ cure rates that rival surgery
- No anesthesia, cutting, bleeding, stitching or pain
- No downtime or lifestyle restrictions
- Super cosmesis, no unsightly scarring
- No need for post-treatment reconstructive surgeries